---
category: news
title: "Machine Learning-Based Classification of the Health State of Mice Colon in Cancer Study from Confocal Laser Endomicroscopy"
excerpt: "In this article, we address the problem of the classification of the health state of the colon’s wall of mice, possibly injured by cancer with machine learning approaches. This problem is essential for translational research on cancer and is a priori challenging since the amount of data is usually limited in all preclinical studies for ..."
publishedDateTime: 2019-12-27T10:29:00Z
sourceUrl: https://www.nature.com/articles/s41598-019-56583-9
type: article
quality: 13
heat: -1
published: false

provider:
  name: Nature
  domain: nature.com

topics:
  - AI
  - Machine Learning

images:
  - url: https://www.bing.com/th?id=ON.F2BD9394E7EA01BECA1A51A5676C816F
    width: 685
    height: 680
    title: "Machine Learning-Based Classification of the Health State of Mice Colon in Cancer Study from Confocal Laser Endomicroscopy"

related:
  - title: "Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL(TM) in Prostate Cancer Achieved Primary Endpoint"
    excerpt: "About PROGENICS Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find ... who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTOR [(R)] (methylnaltrexone bromide) for the treatment of opioid-induced constipation ..."
    publishedDateTime: 2019-12-23T11:00:00Z
    sourceUrl: https://www.marketwatch.com/press-release/progenics-pharmaceuticals-announces-phase-3-condor-trial-of-pyltm-in-prostate-cancer-achieved-primary-endpoint-2019-12-23-7184024
    type: article
    provider:
      name: MarketWatch
      domain: marketwatch.com
    quality: 33
    images:
      - url: https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png
        width: 1200
        height: 630
  - title: "Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint"
    excerpt: "NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find ... conventional imaging and/or changes in PSA levels following radiation therapy. Safety results showed PyL was well tolerated, consistent with the Phase 2 OSPREY ..."
    publishedDateTime: 2019-12-23T15:49:00Z
    sourceUrl: https://finance.yahoo.com/news/progenics-pharmaceuticals-announces-phase-3-120010916.html
    type: article
    provider:
      name: YAHOO!
      domain: yahoo.com
    quality: 0

secured: "rI25oaQ+iKv7SZr7+TlvrDSuymnPheu3fIH7dEreZL5l8vYFI+dio9X9WF+Fkyeph14b0wKWee/iEFRjDzNkNuNLzGWMPM8+jzCMfZf1bHVvpKeNHuIhObjznDDwmeIMMxUH6u8miwAR8pcIBOCl33w1HO4PWP9ZxcEy5VqAya1Ioaz+gACISS77iRySQ5Kgy/+OEAt8hOT9EGMNwF6avQfrSzkD8nWCExcSsE5TX40hhzbCaWmfKU9BCYEIH+NDUoIbbEW3aAUDCEqoPldwMg==;CcV0sfP+OLqV41BLIp2Lmw=="
---

